Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +2.38%23 3-Year EBITDA Growth Rate is 95.60% as of Mar. 2026, which is 6% above its 10-year median of 89.85. GuruFocus rates NSE:ACCPL with a GF Score™ of 23/100. The stock has 6 warning signs investors should review. Among 808 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 97.28% on this metric.
During the past 12 months, Accretion Pharmaceuticals's average EBITDA Per Share Growth Rate was 30.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 95.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Accretion Pharmaceuticals was 95.60% per year. The lowest was 84.10% per year. And the median was 89.85% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Accretion Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
NSE:ACCPL vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 95.60% mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a 3-Year EBITDA Growth Rate of 95.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Accretion Pharmaceuticals and its competitors. This is near median its historical median of 89.85. Over the past decade, Accretion Pharmaceuticals' 3-Year EBITDA Growth Rate has ranged from 84.10 to 95.60. According to the industry distribution chart, Accretion Pharmaceuticals ranks #22 out of 808 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Accretion Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Accretion Pharmaceuticals' current 3-Year EBITDA Growth Rate of 95.60% is near median its 10-year median of 89.85. Over the past 10 years, this metric has ranged from a low of 84.10 to a high of 95.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Accretion Pharmaceuticals' value of 95.60% is 974.2% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #22 out of 808 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #22 out of 808 companies for 3-Year EBITDA Growth Rate. This places Accretion Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Accretion Pharmaceuticals' value of 95.60% is 974.2% above this benchmark. Historically, Accretion Pharmaceuticals' own 3-Year EBITDA Growth Rate has ranged from 84.10 to 95.60 over the past decade. While the company's 10-year median is 89.85 vs. the industry median of 8.90, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current 3-Year EBITDA Growth Rate of 95.60% is 974.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current 3-Year EBITDA Growth Rate is 95.60%, which is near median its own 10-year median of 89.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current 3-Year EBITDA Growth Rate of 95.60%. The current 3-Year EBITDA Growth Rate is 95.60%, which is near median its 10-year median of 89.85 and 974.2% above the Drug Manufacturers industry median of 8.90. Accretion Pharmaceuticals' overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current 3-Year EBITDA Growth Rate is 95.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
23GF Score
Get the complete analysis for NSE:ACCPL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
